Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | GLB1 | P16278 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14751750 | 0.83 | GBA1 (0.46) | GBA1HSD11B1CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL23598176 | 0.82 | GBA1 (0.42) | GBA1HSD11B1CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL6750686 | 0.80 | HRH3 (0.49) | HRH3HSD11B1 | |
| SCHEMBL18756406 | 0.80 | GBA1 (0.41) | GBA1GLB1SLC6A3 | |
| SCHEMBL22006103 | 0.79 | KCNH2 (0.33) | HRH3KCNH2 | |
| SCHEMBL20888184 | 0.78 | GBA1 (0.46) | GBA1HSD11B1CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL23870212 | 0.77 | GBA1 (0.39) | GBA1HRH3HSD11B1 | |
| SCHEMBL20888183 | 0.77 | GBA1 (0.44) | GBA1HSD11B1CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL14768541 | 0.77 | GBA1 (0.44) | GBA1HSD11B1CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL19399848 | 0.77 | GBA1 (0.44) | GBA1HSD11B1CYP2D6SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022109426-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| EP-3434668-B1 | INDOLO-SUBSTITUTED-PIPERIDINE COMPOUNDS AS ESTROGEN RECEPTOR DEGRADING AGENT | LUOXIN PHARMACEUTICAL SHANGHAI CO LTD (CN) | 2020-08-26 | — | — | EP | disclosed |
| US-20190106414-A1 | SUBSTITUTED-INDOLE-COMPOUNDS AS ESTROGEN RECEPTOR DOWN-REGULATORS | Luoxin Healthcare Science and Technology Development (Beijing) Ltd. (CN) | 2019-04-11 | — | — | US | disclosed |
| EP-3434668-A1 | INDOLO-SUBSTITUTED-PIPERIDINE COMPOUNDS AS ESTROGEN RECEPTOR DEGRADING AGENT | Luoxin Biotechnology (Shanghai) Co., Ltd. (CN) | 2019-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190106414-A1 | SUBSTITUTED-INDOLE-COMPOUNDS AS ESTROGEN RECEPTOR DOWN-REGULATORS | ESR2, ESR1, GPER1 | GBA1 4885/4885HRH3 2433/4885HSD11B1 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.